Zhitong Finance App News, Anke Biotech (300009.SZ) issued an announcement. Recently, Shanghai Soho Yiming Pharmaceutical Co., Ltd. (hereinafter referred to as “Sohao Yiming”), a wholly-owned subsidiary of Anhui Anke Bioengineering (Group) Co., Ltd., received the “Chemical Ingredient Marketing Application Approval Notice” issued by the State Drug Administration.

The approval and listing of the teripressin acetate API indicates that the product has qualified for entry into the domestic market. It is conducive to enriching the company's peptide API product pipeline, promoting the growth of the API sales business, further broadening the company's peptide business layout, and enhancing core competitiveness.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.